Efficacy and safety of BORTEZOMIB treatment for refractory acute antibody-mediated rejection - a pilot study

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F18%3A00077422" target="_blank" >RIV/00023001:_____/18:00077422 - isvavai.cz</a>

Výsledek na webu

<a href="https://onlinelibrary.wiley.com/doi/abs/10.1111/tan.13387" target="_blank" >https://onlinelibrary.wiley.com/doi/abs/10.1111/tan.13387</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/tan.13387" target="_blank" >10.1111/tan.13387</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Efficacy and safety of BORTEZOMIB treatment for refractory acute antibody-mediated rejection - a pilot study

Popis výsledku v původním jazyce

A novel therapeutic approach to refractory acute antibody-mediated rejection (AMR) in kidney transplant recipients was applied in 23 patients based on administration of Bortezomib, intravenous corticosteroids, plasmapheresis and Rituximab. Application of Bortezomib regimen led to diminishing of donor-specific antibodies (DSA) to HLA-B (P = 0.004) and HLA-DR (P = 0.0005), but not to HLA-A (P = 0.106) and HLA-DQ antigens (P = 0.18). Patients with good clinical response to treatment had significantly better allograft survival than recipients with continuing deterioration of graft function (P = 0.019). Graft survival after therapy of refractory AMR was significantly worse than survival after first transplantation and was comparable with outcomes after retransplantation. In conclusion, therapy with Bortezomib was well tolerated and effective in decreasing the levels of HLA-B and -DR antibodies, however, was not successful in depleting HLA-A and -DQ DSA.

Název v anglickém jazyce

Efficacy and safety of BORTEZOMIB treatment for refractory acute antibody-mediated rejection - a pilot study

Popis výsledku anglicky

A novel therapeutic approach to refractory acute antibody-mediated rejection (AMR) in kidney transplant recipients was applied in 23 patients based on administration of Bortezomib, intravenous corticosteroids, plasmapheresis and Rituximab. Application of Bortezomib regimen led to diminishing of donor-specific antibodies (DSA) to HLA-B (P = 0.004) and HLA-DR (P = 0.0005), but not to HLA-A (P = 0.106) and HLA-DQ antigens (P = 0.18). Patients with good clinical response to treatment had significantly better allograft survival than recipients with continuing deterioration of graft function (P = 0.019). Graft survival after therapy of refractory AMR was significantly worse than survival after first transplantation and was comparable with outcomes after retransplantation. In conclusion, therapy with Bortezomib was well tolerated and effective in decreasing the levels of HLA-B and -DR antibodies, however, was not successful in depleting HLA-A and -DQ DSA.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30217 - Urology and nephrology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2018

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

HLA

ISSN

2059-2302

e-ISSN

—

Svazek periodika

92

Číslo periodika v rámci svazku

Suppl. 2

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

4

Strana od-do

47-50

Kód UT WoS článku

000454095400005

EID výsledku v databázi Scopus

2-s2.0-85058900916